Skip to main content

Heart Failure News (Page 6)

Related terms: CHF

New Heart Implant Monitors, Treats -- and Then Dissolves Away

FRIDAY, July 7, 2023 – An experimental implant now under development could serve as a temporary monitor and pacemaker for ailing heart patients – then dissolve away when it’s no longer needed. The s...

Metabolic Surgery Cuts Cardiovascular Events for Obesity, Sleep Apnea

THURSDAY, July 6, 2023 – Metabolic surgery is associated with a lower risk for major adverse cardiovascular events (MACE) in patients with obstructive sleep apnea (OSA) and obesity, according to a...

Injectafer Approved in the U.S. for the Treatment of Iron Deficiency in Adult Patients with Heart Failure

BASKING RIDGE, N.J. & SHIRLEY, N.Y.--(BUSINESS WIRE) June 05, 2023 --Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug...

FDA Approves Inpefa (sotagliflozin) for the Treatment of Heart Failure

THE WOODLANDS, Texas, May 26, 2023 (GLOBE NEWSWIRE) – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has approved Inpefa™ (...

FDA Approves Furoscix (furosemide injection) for the At-Home Treatment of Congestion Due to Fluid Overload in Chronic Heart Failure

Furoscix demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) – scPharmaceuticals...

US FDA Approves Jardiance (empagliflozin) to Treat Adults with Heart Failure Regardless of Left Ventricular Ejection Fraction

RIDGEFIELD, Conn. and INDIANAPOLIS, Feb. 24, 2022 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Jardiance® (empagliflozin) 10 mg to reduce the risk of cardiovascular death ...

FDA Approves Soaanz (torsemide) for Edema Treatment in Patients with Heart Failure and Renal Disease

VIENNA, VA. (PRWEB) JUNE 21, 2021 Sarfez Pharmaceuticals announced today approval by the U.S. Food and Drug Administration (FDA) of the Virginia-based company’s New Drug Application for Soaanz, a o...

Entresto Granted Expanded Indication in Chronic Heart Failure by FDA

EAST HANOVER, N.J., Feb. 16, 2021 -- Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to red...

FDA Approves Verquvo (vericiguat) for Heart Failure with Reduced Ejection Fraction

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Verquvo, a...

Farxiga Approved in the US for the Treatment of Heart Failure in Patients with Heart Failure with Reduced Ejection Fraction

6 May 2020 – AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death and hospitalisation for heart failure in adults with heart failure (...

FDA Approves Farxiga (dapagliflozin) to Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes

21 October 2019 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalization for heart failure (hHF) in...

FDA Approves Entresto (sacubitril/valsartan) for Pediatric Heart Failure

East Hanover, N.J., Oct. 1, 2019 – Novartis announced today that the U.S. Food and Drug Administration (FDA) has approved Entresto (sacubitril/valsartan) for the treatment of symptomatic heart f...

Medicure Announces FDA Approval Received for Prexxartan (valsartan) Oral Solution

WINNIPEG, Dec. 19, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today announced that Carmel Biosciences, Inc. ("Carmel") has...

CMP Pharma, Inc. Announces FDA Approval of CaroSpir (spironolactone) Oral Suspension

Farmville, NC. August 7, 2017 – CMP Pharma today announced that the US Food and Drug Administration (FDA) has granted final approval of the company’s New Drug Application (NDA) for CaroSpir (Sp...

FDA Approves Qbrelis (lisinopril) Oral Solution for Pediatric Patients 6 Years of Age and Older

Denver, July 29, 2016 — Silvergate Pharmaceuticals, Inc., leader in the development and commercialization of innovative and safe medicines for children, today announced that the United States Food a...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Left Ventricular Dysfunction, Cardiovascular Conditions and Disorders

Related drug support groups

lisinopril, metoprolol, warfarin, Coumadin, spironolactone, triamcinolone, carvedilol, Metoprolol Succinate ER, diltiazem, view more... Lasix, furosemide, bisoprolol, valsartan, Entresto, Farxiga, ramipril, Jardiance, digoxin, prazosin, Diovan, nitroglycerin, Coreg